BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), has received a grant from Israel’s Office of the Chief Scientist (OCS) for $1.1 million (NIS 3.8 million) . BrainStorm is performing a Phase I/II human clinical trial in Israel with the company’s adult stem cell therapy in patients with ALS, often referred to...
Read more